We are live on ! Find out more
DYN icon

Dyne Therapeutics
DYN

90 hedge funds and large institutions have $321M invested in Dyne Therapeutics in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 31 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

2.05% less ownership

Funds ownership: 92.43% → 90.39% (-2%)

4% less funds holding

Funds holding: 94 → 90 (-4)

16% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 31

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

30% less capital invested

Capital invested by funds: $457M → $321M (-$136M)

Holders
90
Holders Change
-4
Holders Change %
-4.26%
% of All Funds
1.52%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
9
Increased
26
Reduced
31
Closed
11
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$6K

Top Buyers

1
Franklin Resources
Franklin Resources
California
+$3.92M
2
Citigroup
Citigroup
New York
+$2.72M
3
UOC
UBS O'Connor
Illinois
+$1.57M
4
LGM
Logos Global Management
California
+$1.14M
5
BlackRock
BlackRock
New York
+$754K

Top Sellers

1
Norges Bank
Norges Bank
Norway
-$5.78M
2
OCA
Octagon Capital Advisors
New York
-$5.06M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.59M
4
IBT
International Biotechnology Trust
United Kingdom
-$3.25M
5
CC
Commodore Capital
New York
-$2.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$61.4M – – –
MAM
2
MPM Asset Management
Massachusetts
$34M – – –
DTC
3
Deep Track Capital
Connecticut
$24M – – –
VVA
4
Vida Ventures Advisors
Massachusetts
$20.3M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$20.1M -$252K -36,619 -1%
LGM
6
Logos Global Management
California
$19.9M +$1.14M +165,608 +6%
RCM
7
RA Capital Management
Massachusetts
$19.3M – – –
BlackRock
8
BlackRock
New York
$17M +$754K +109,517 +5%
Franklin Resources
9
Franklin Resources
California
$12M +$3.92M +568,533 +48%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$9.39M -$3.59M -521,500 -28%
Vanguard Group
11
Vanguard Group
Pennsylvania
$9.08M -$501K -72,716 -5%
Janus Henderson Group
12
Janus Henderson Group
United Kingdom
$7.29M -$843K -122,405 -10%
HA
13
HHLR Advisors
Cayman Islands
$6.87M – – –
WP
14
Woodline Partners
California
$4.58M -$1.01M -146,142 -18%
VC
15
Vivo Capital
California
$3.97M – – –
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$3.92M -$1.24M -180,000 -24%
State Street
17
State Street
Massachusetts
$3.85M +$405K +58,717 +12%
AG
18
Artal Group
Luxembourg
$3.61M – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$3.43M +$71.1K +10,316 +2%
CS
20
Candriam SCA
Luxembourg
$2.84M +$622K +90,231 +28%
Citigroup
21
Citigroup
New York
$2.77M +$2.72M +395,230 +5,322%
Marshall Wace
22
Marshall Wace
United Kingdom
$2.4M – – –
MIM
23
Monashee Investment Management
Massachusetts
$2.19M +$274K +39,832 +14%
Assenagon Asset Management
24
Assenagon Asset Management
Luxembourg
$1.83M -$197K -28,617 -10%
Northern Trust
25
Northern Trust
Illinois
$1.83M +$64.6K +9,374 +4%
1
2 3 4

DYN Hedge Fund Activity: Q2 2022 in Review

90 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2022, worth a combined $321M — down 30% from $457M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of DYN and 9 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 26 added.

The largest buyer was Franklin Resources, adding an estimated $3.92M. The largest seller was Norges Bank, exiting entirely with an estimated $5.78M sold.

  • 90 institutional investors held Dyne Therapeutics (DYN) as of Q2 2022, down from 94 in Q1 2022.
  • Funds reported $321M of Dyne Therapeutics stock for Q2 2022, down 30% quarter-over-quarter.
  • 9 funds opened new Dyne Therapeutics positions in Q2 2022 and 11 closed out, a net change of -2 holders.
  • The largest Dyne Therapeutics buyer in Q2 2022 was Franklin Resources, an estimated $3.92M added.
  • The largest Dyne Therapeutics seller in Q2 2022 was Norges Bank, an estimated $5.78M sold.

Based on aggregated 13F filings for Q2 2022.